Q-omics provides the consensus-scored SLX1B-SULT1A4 profile across patient tissues and cancer cell-line models. SLX1B-SULT1A4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLX1B-SULT1A4 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, SLX1B-SULT1A4 RNA expression shows 6,210 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight KIRC, and BRCA as cancer lineages where SLX1B-SULT1A4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLX1B-SULT1A4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLX1B-SULT1A4 survival associations across molecular data types. SLX1B-SULT1A4 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLX1B-SULT1A4 RNA expression–survival associations across cancer types. High SLX1B-SULT1A4 expression shows unfavorable associations in KIRC, COAD, DLBC, BRCA and UCEC, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLX1B-SULT1A4 RNA expression.
This table summarizes SLX1B-SULT1A4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SLX1B-SULT1A4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLX1B-SULT1A4 shows higher tumor expression in BRCA, STAD, LUSC, HNSC and BLCA. The BRCA box plot shows higher SLX1B-SULT1A4 RNA expression in tumor versus normal tissue (log2 FC = +0.007, t-test p < 0.001).
This table shows molecular features associated with SLX1B-SULT1A4 in patient tissues and cancer cell lines. In patient samples, SLX1B-SULT1A4 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
